Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors

Disease:

HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer

Study phase:

Physician name:

Ecaterina Ileana Dumbrava

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-877-421-1842